Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Investor Presentation (November 2022)
28 slides from Valiant Organics's investor presentation, Nov 30, 2022
Slide 1: Covering letter to BSE and NSE: Investor Presentation
November 30, 2022 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza “Plot No .C/1, Mumbai – 400 001. G Block Bandra –Kurla Complex, Bandra (E), Mumbai -400051. Scrip Code-5401
Slide 2: Investor Presentation | November 2022
Investor Presentation | November - 2022 1
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
eeee Valiant O1 9000 COMPANY OVERVIEW
Slide 5: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 6: Board of Directors
Board of Directors Shri Velji K. Gogri – Chairman, Independent Director Chemical Engineer having 37 years of experience in the chemical industry, graduated Shri Vishnu J. Sawant – Executive Director from IIT Mumbai. A number of manufacturing units for bulk pharmaceuticals, Has nearly 3 decades of ex
Slide 7: Key Milestones
Key Milestones Expanded product range to Listed on BSE Main Board; include Chlorophenols, for Commenced Ammonolysis Received Environmental usage in intermediates in expansion at Vapi unit; clearance to enhance Pharmaceuticals, Commenced Converted into Limited Completed backward Chlorophenol capacity
Slide 8: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 28,800 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 9: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 10: Capex Projects
Capex Projects Product Project Status Remarks Commissioned Para Nitro Aniline (PNA) & Ortho Chloro Completing phase-wise • Expansion from 550 TPM to 750 TPM at Vapi plant Para Nitro Aniline (OCPNA) • Full capacity addition in progress Ortho Nitro Anisole (ONA) Completed in Q4 FY’20 • Backward integr
Slide 11: Business Overview
seco Valiant Organics Limited 9000 BUSINESS OVERVIEW
Slide 12: Chemistries And Product Basket
Chemistries And Product Basket H1-FY23 Revenue Share Hydrogenation Ammonolysis 45% Key Products: Industries Served: Key Products: • Ortho Anisidine • Dyes Industries Served: • Para Anisidine • Pigments • Para Nitro Aniline • Dyes • Ortho Chloro Para Nitro Aniline • IPPCA • Pharmaceutical • Pigments
Slide 13: Chlorination
Chlorination Any reaction in which chlorine or chlorine compounds are introduced into a molecule to obtain the desired Revenues (INR Mn)* outcome is known as chlorination. 3, 000 2,765 • Valiant is the only domestic player and also a global leader in Chlorophenol products with ~25% global market 2,
Slide 14: Ammonolysis
Ammonolysis Ammonolysis is a high-pressure chemical reaction done in an auto clave where ammonia is used as a reactant. Revenues (INR Mn)* • Valiant developed Ammonolysis capabilities as a result of its two acquisitions. i.e. Abhilasha Tex Chem Pvt. Ltd. 3, 500 2,917 in 2017 & Amarjyot Chemicals Ltd
Slide 15: Hydrogenation
Hydrogenation Hydrogenation is a chemical reaction between molecular hydrogen (H2) and another compound or element, usually in the presence of a catalyst. Revenues (INR Mn)* • The company has manufacturing facilities in Jhagadia for Hydrogenation. The first unit (also named as Unit 1) 3, 500 has a c
Slide 16: Other Processes
Other Processes Acetylation Revenues (INR Mn)* Acetylation is a chemical reaction which introduces an acetyl functional group into a chemical compound. 855 • The acetylation procedure is carried out at the company’s Ahmedabad facility which has a capacity of 1,800 900 800 MTPA 700 600 530 • The key
Slide 17: Industry Overview
seco Valiant Organics Limited 9000 INDUSTRY OVERVIEW
Slide 18: Industry Overview
Industry Overview • The chemicals industry in India covers more than 80,000 commercial products. Global Chemical Market (USD Bn) th th • India is 6 largest manufacturer of chemicals in the world and 4 largest in Asia. Commodi ty Chemicals 8, 000 • The Indian chemical industry was pegged at USD 178 b
Slide 19: Advantage India: Key Growth Factors
Key Growth Factors GROWING OPPORTUNITIES POLICY INCREASING ADVANTAGE INDIA DEMAND SUPPORT INVESTMENT • Rise in demand from end-users • Supply disruption in China has • The government plans to Industries such as food processing, caused the global end-user • India’s specialty chemical introduce produc
Slide 20: Financial Overview
seco Valiant Organics Limited 9000 FINANCIAL OVERVIEW
Slide 21: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY20 FY21* FY22* H1-FY23* Operational Income 6,749 7,548 11,533 5,300 Total Expenses 4,946 5,496 9,484 4,563 EBITDA 1,803 2,052 2,049 737 EBITDA Margins (%) 26.71% 27.19% 17.77% 13.91% Other Income 63 59 74 38 Depreciation 158 212 296 139
Slide 22: Consolidated Balance Sheet (IND-AS)
Consolidated Balance Sheet (IND-AS) Particulars (INR Mn) FY21 FY22 H1-FY23 Particulars (INR Mn) FY21 FY22 H1-FY23 EQUITY 5,086 6,489 6,816 Non-Current Assets 5,731 6,652 7,000 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 4,967 5,303 5,375 b) Other Equity 4,747 5,856 6,121 b)
Slide 23: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY20 FY21* FY22* H1-FY23* Revenue from Operations 5,836 5,742 9,484 4,669 Total Expenses 4,103 4,170 7,834 4,094 EBITDA 1,733 1,572 1,650 575 EBITDA Margins (%) 29.69% 27.38% 17.40% 12.32% Other Income 52 169 56 16 Depreciation 130 186 273
Slide 24: Standalone Balance Sheet (IND-AS)
Standalone Balance Sheet (IND-AS) Particulars (INR Mn) FY21 FY22 H1-FY23 Particulars (INR Mn) FY21 FY22 H1-FY23 EQUITY 5,023 6,031 6,240 Non-Current Assets 5,798 6,787 7,094 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 4,771 5,085 5,143 b) Other Equity 4,747 5,755 5,964 b) Ca
Slide 25: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 80.00% 1,282 1,309 1,279 2,052 1, 400 2,049 14, 000 11,533 2,100 12, 000 1,803 70.00% 1,800 1, 100 10, 000 60.00% 1,500 50.00% 7,548 800 8, 000 6,749 1,200 40.00% 5,300
Slide 26: Capital Market Information
Capital Market Information 30% Share Price up to 30th September, 2022 20% 10% 0% -10% -20% -30% -40% -50% -60% -70% Oct/21 Nov/21 Dec/21 Jan/22 Feb/22 Mar/22 Apr/22 May/22 Jun/22 Jul/22 Aug/22 Sep/22 Valiant Sensex Price Data (As on 30th September, 2022) INR Shareholding pattern (As on 30th Septembe
Slide 27: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 28: Thank You
eeee Valiant O1 9000 THANK YOU
Valiant Organics — Investor Presentation (November 2022) on 6ix